Acquired Immunodeficiency Syndrome: Meeting of the WHO
Collaborating Centres on AIDS
Following a consultation on acquired immunodeficiency syndrome
(AIDS) in April 1985, the World Health Organization (WHO)
a network of Collaborating Centres on AIDS to provide a framework
international cooperation, including training, provision of
reagents, evaluation of methods, and epidemiologic surveillance
The directors of the WHO Collaborating Centres, together with other
experts in virology and public health, met in Geneva, Switzerland,
September 25-26, 1985, to make recommendations for WHO's 1986-1987
international activities on AIDS.
Participants at the meeting reviewed the epidemiologic status
AIDS and affirmed the disease was now a major public health problem
several countries of the developed and developing world. Over
AIDS cases were reported from 1981 to September 1985 in the United
States, and the number of reported cases will probably double in
1986. More than 2,000 cases have been reported from 40 other
countries. The Director-General of WHO expressed the great degree
concern felt in almost all 166 Member States of WHO regarding AIDS.
In the United States and western Europe, approximately 90% of
cases among adults continued to occur in homosexual and bisexual
intravenous drug users, and sexual partners of persons in these
groups. Although it is expected that additional AIDS cases may
develop in recipients of blood and blood products who are already
infected with the causative virus of AIDS,
virus/human T-lymphotropic virus type III (LAV/HTLV-III), future
infections from blood and blood products can now virtually be
considered preventable by screening blood donations for evidence of
antibodies to the virus. Most pediatric cases of AIDS have
among children of persons in known risk groups. In several
countries, however, most adult AIDS patients have been sexually
heterosexual men and women.
There is no evidence that LAV/HTLV-III is spread through casual
contact with an infected individual, such as contact in family
settings, schools, or other groups living or working together. The
risk of infection of health-care workers seems very remote. At
present, there is no evidence that blood-sucking insects transmit
The group concluded that an internationally accepted case
definition of AIDS, relevant to its most severe clinical
manifestations, was needed for surveillance purposes. For
trials or other research purposes, broader definitions may be
In countries where appropriate technologies are available, the
surveillance definition for AIDS given by CDC and published by WHO
was endorsed by the group. Surveillance definitions are now being
developed for use in countries where access to diagnostic
The group concurred on the following issues:
For routine, large-scale testing for AIDS, the only
methods currently available involve tests for antibodies
All sera reactive for anti-LAV/HTLV-III antibody in a
radioimmunoassay (RIA) or enzyme-linked immunoabsorbent
(ELISA) test should be confirmed by an independent test
system, e.g., by immunoprecipitation or immunoblot tests.
Assays for this antibody of higher specificity but lower
sensitivity than that of conventional commercial ELISAs
be more appropriate for seroepidemiologic studies where
confirmatory tests are not available.
Posttransfusion AIDS can be eliminated by excluding donors
from groups at increased risk of infection and by
all units of blood for antibodies to LAV/HTLV-III.
infection can be transmitted from women to babies during
perinatal period, women who are antibody-positive should
advised to avoid pregnancy.
Reusing unsterile needles carries with it the risk of
transmitting AIDS and other blood-borne infections. This
procedure should be strongly discouraged.
The possible transmission of infectious diseases through
use of jet injection devices was discussed. After
considering the available information, the group concluded
that there was no evidence of a risk of transmission of
blood-borne infection from using such devices.
Studies to identify effective therapeutic regimens for
patients and work on developing vaccines are in progress
several countries. Successful therapy may require a
combination of antiviral agents and substances that
immune responsiveness. Passive protection against
is being pursued experimentally, including the use of
monoclonal antibodies and hyperimmune gammaglobulin.
work towards understanding the role of antibody in
and treating AIDS is required before these substances can
utilized in patients.
New antiviral drugs require careful study using the
procedures of classical drug-evaluation protocols, under
guidelines of national control authorities. Studies to
define the pharmacology, toxicity, and tolerated dosages
precede studies to determine the benefit.
Placebo-controlled studies in patients with mild forms of
disease due to LAV/HTLV-III infection should be
Such studies will yield an answer on the efficacy of a
more quickly and with fewer patients than the use of
The prevalence of AIDS will depend heavily on the success
risk-reduction programs based on public information and
Because patients infected with LAV/HTLV-III often have
immune-function abnormalities, administration of the
used live-virus vaccines (e.g., polio, measles) to such
individuals could pose a theoretical risk. However, to
no unexpected adverse reactions have been noted in
individuals with antibody to LAV/HTLV-III, and such
are free of overt signs of clinical AIDS when given the
vaccines recommended by WHO for childhood or adult
T-lymphotropic retroviruses of simians provide potentially
valuable models for studying the control and treatment of
An important aspect of WHO activities on AIDS will be the
collection of data on the incidence of the disease or its
causative virus by Member States and the WHO Collaborating
Centres and the regular transmission of this information
WHO headquarters. Wherever possible, information on the
gender, age, recognized risk factor (if any), and major
clinical features should also be provided
A full report of the meeting is available from the Director,
Division of Communicable Diseases, WHO, Geneva.
Adapted from WHO Weekly Epidemiological Record 1985;60:333-5.
WHO. Acquired immune deficiency syndrome (AIDS). WHO
consultation. Weekly Epidemiological Record 1985;60:129-30.
WHO. Acquired immune deficiency syndrome (AIDS). Revision of
case definition of AIDS. Weekly Epidemiological Record
WHO. T-lymphotropic retroviruses of non-human primates. WHO
informal meeting. Weekly Epidemiological Record
All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.**Questions or messages regarding errors in formatting should be addressed to email@example.com.
Page converted: 08/05/98